Background {#Sec1}
==========

Perioperative neurocognitive disorder (PND) is a recently recommended overarching term for cognitive impairment in the preoperative or postoperative period and is associated with increased mortality \[[@CR1]\]. It is characterized as a decline in cognitive functions including memory, attention, information processing and cognitive flexibility \[[@CR2]\]. It has been reported that advanced age is one of the major risk factors \[[@CR3]\]. However, the pathogenesis underlying PND still remains unknown. Increasing evidence suggests that neuroinflammation is a key contributor to PND \[[@CR4], [@CR5]\]. Li et al. have shown that early postoperative inflammation is important for neurodevelopment-associated outcomes 2 years after the Norwood procedure \[[@CR6]\]. Surgical trauma leads to an increase in systemic inflammatory mediators, such as Il-β and IL-6, which have been shown to influence neuroinflammatory cascade in the brain and impair cognitive function \[[@CR7]\]. In addition, the ageing process itself has been associated with enhanced neuroinflammatory response and more pro-inflammatory cytokines \[[@CR8], [@CR9]\].

The BBB is an important structure that separates the central nervous system (CNS) from the periphery, protects the brain from harm and maintains homeostasis in the brain. BBB disruption allows the entry of neurotoxic debris, cells and pathogens and contributes to inflammatory and immune responses in the CNS \[[@CR10]\]. BBB breakdown has been found in several autoimmune and neurodegeneration diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS) \[[@CR11]--[@CR13]\]. Some research has shown age-dependent BBB breakdown in the hippocampus, which may be associated with cognitive decline during ageing \[[@CR14], [@CR15]\]. Recent findings have suggested that BBB disruption is prevalent in the first 24 h after surgery, and dysfunction of the BBB may facilitate the passage of peripheral immune cells and mediators to the brain, which promotes brain inflammation and neuronal damage \[[@CR16], [@CR17]\].

IL-17 is mainly secreted by T helper 17 (Th17) cells, and the IL-17 family includes six members designated IL-17A-F, among which IL-17A is the most important member. IL-17A is emerging as a crucial pro-inflammatory cytokine contributing to the occurrence and development of several CNS inflammatory diseases \[[@CR18], [@CR19]\]. Some researches revealed that some clinical drugs to alleviate neuroinflammation in multiple sclerosis worked through regulating Th17 cell differentiation \[[@CR20], [@CR21]\]. Our previous data indicated that IL-17A was involved in LPS-induced cognitive impairment in aged rats \[[@CR22]\]. What is more, IL-17 levels in the supernatant of drainage fluid from patients received colectomies via laparotomy rapidly reached the maximum 1--2 days after surgery \[[@CR23]\]. In an experimental autoimmune encephalomyelitis (EAE) model, IL-17A induced BBB breakdown by reactive oxygen species (ROS) production and a decrease in tight junctions (TJs) \[[@CR24]\]. In consideration of the role of IL-17A in CNS inflammation and the impact on BBB permeability in the EAE model and to further decipher the role of IL-17A on BBB function in PND, we used a tibial fracture surgical model in aged mice. Human anti-IL-17A antibody has been tested clinically and shown proven efficacy and safety in chronic inflammatory diseases \[[@CR25]--[@CR27]\]. What is more, an in vitro experiment showed that secukinumab, the FDA-approved anti-IL-17 antibody, could rescue the neuronal death from Parkinson's disease patients \[[@CR28]\]. In view of the clinical study of human anti-IL-17 antibody, it is of great clinical significance and application value to explore the role of IL-17A in PND. We hypothesized that surgical trauma induces the release of IL-17A and drives the BBB breakdown, promoting the inflammatory response in the CNS and finally leading to cognitive dysfunction.

Materials and methods {#Sec2}
=====================

Reagents {#Sec3}
--------

Dulbecco's modified Eagle's medium (DMEM), 0.25% trypsin-EDTA solution and foetal bovine serum (FBS) were purchased from Gibco-BRL (Grand Island, NY, USA). Mouse IL-17A and isotype-control Abs were purchased from R&D Systems (Minneapolis, MN, USA). Monoclonal mouse anti-MMP-2, monoclonal mouse anti-MMP-9 and monoclonal rabbit anti-occludin were purchased from Abcam (Hong Kong, China). Monoclonal mouse anti-claudin-5 antibody was purchased from Invitrogen (Invitrogen, USA). Recombinant IL-17A protein and Fluoroshield mounting medium with 4,6-diamidino-2-phenylindole (DAPI) were purchased from Abcam (Hong Kong, China). The mouse IL-17A ELISA kit, IL-6 ELISA kit and IL-1β ELISA kit were obtained from R&D Systems (Minneapolis, MN, USA).

In vivo studies {#Sec4}
---------------

### Animals {#Sec5}

Male wild-type C57BL/6J mice (15 months old) were purchased from Jinling Hospital of Nanjing University. All mice were housed in groups of five animals per cage with free access to food and water under standard laboratory conditions, a 12/12-day/night cycle and a constant room temperature of 22 ± 1 °C. All experimental procedures were approved by the Nanjing Medical University Animal Care and Use Committee and performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health of the United States.

### Design and treatment groups {#Sec6}

The mice were randomly allocated to 4 groups with 12 mice in each group: (i) control group (Con group), (ii) tibial fracture surgery group (Sur group), (iii) tibial fracture surgery following i.p. injection of anti-IL-17A Abs group (Sur+anti-IL-17A group) and (iv) tibial fracture surgery following i.p. injection of isotype-control Abs group (Sur+isotype group). Mice in the Sur+anti-IL-17A group received 3 mg/kg anti-IL-17A Abs, and those in the Sur+isotype group received 3 mg/kg isotype-control Abs 30 min before surgery. One day before surgery, mice were performed behavioural training, and behavioural test was performed 1 day after surgery. Following behavioural test, Evans blue (EB) extravasations were detected and hippocampus tissues and serums were collected. The study design is briefly illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study design. **a** Experiment 1: TFC test training was performed 1 day before surgery. Mice in the Con+anti-IL-17A group received i.p. anti-IL-17A Abs, and the Con+isotype group received an equivalent dose of isotype-control Abs 30 min before surgery. Behavioural tests included TFC and the Y maze performed 24 h after surgery, and then the hippocampi were collected. **b** Experiment 2: After behavioural tests, the mice received an intravenous injection of EB, and the hippocampi were collected for EB extravasation detection

### Surgery {#Sec7}

Following isoflurane anaesthesia (2.0% inspired concentration in 40% FiO2), open tibial fracture surgery was performed as previously described \[[@CR29], [@CR30]\]. Briefly, the left tibia was shaved and disinfected, and a middle incision lateral to the tibia was made, followed by insertion of an intramedullary fixation pin in the bone marrow cavity. Then, we stripped the periosteum and performed an osteotomy at the junction of the middle and upper third of the tibia under direct vision. Finally, the wound was sterilized and sutured, and analgesia (buprenorphine 0.1 mg/kg subcutaneously) was injected subcutaneously. During the procedure, a sterile surgical field was maintained and a heating pad was used to maintain the body temperature.

Behavioural analyses {#Sec8}
--------------------

### Contextual fear conditioning {#Sec9}

Contextual fear conditioning has been used to assess learning and memory in rodents. Mice were trained to associate the environment (context) with the conditional stimulus (tone) and the unconditional stimulus (foot shock). Mice were placed in the conditioning chamber and allowed exploration of the environment for 100 s. Then, the conditional stimulus, an auditory cue (65 dB, 3 kHz), was presented for 20 s, and the unconditional stimulus, a foot shock (0.7 mA, 0.5 s), was performed after termination of the tone. After an interval of 100 s, the procedure was repeated. Mice were removed from the chamber 30 s after the procedure. Finally, we performed a contextual assessment 24 h after surgery but with no cues (tone or shock) in the same chamber. Freezing behaviour (the absence of all movement except for respiration) was recorded for 300 s by video and analysed by software (Xeye Fcs, Beijing Macro Ambition S&T Development Co., Ltd., Beijing, China). All tests were performed blindly by an investigator.

### Y maze test {#Sec10}

The Y maze was composed of three arms (regions I--III, 30 cm l × 5 cm w × 20 cm h) with a lamp at the distal end of each arm, which converged to the equilateral triangular central area. The safe region was illuminated, and the other regions had electrical foot stimulation (25 V). First, each mouse was placed randomly at the end of one arm and allowed to explore the environment for 3 min. Then, the test was started, and the illuminated arm (safe region) served as the new starting area. Next, we changed the orientation of the safe region and stimulation region randomly. The standard of success (learned) was reaching the safe region within 10 s. After each stimulation, we waited for the mouse to reach the illuminated arm before the next stimulation and recorded which arm was chosen to be the new starting area. If nine responses were correct in ten consecutive stimulations (9/10 standard), the mice were considered as having reached learning criterion. We recorded the total number of stimulations to reach criterion as the learning ability during training. All tests were performed blindly by an investigator.

### EB extravasation {#Sec11}

BBB permeability was evaluated by EB (EB; Sigma) extravasation. First, 2% EB (4 ml/kg) was injected intravenously and allowed to circulate for 1 h. Following anaesthesia, mice were perfused with 20 ml normal saline through the left ventricle. The hippocampus was extracted and immersed in formamide (Sigma-Aldrich) for 72 h at 37 °C. Then, formamide was centrifuged at 12,000*g* for 20 min. The absorbance of the hippocampus was measured at 632 nm (BioTek, Vermont, USA). The EB content was calculated from the standard EB curve to measure BBB permeability.

### Immunohistochemistry {#Sec12}

Mice were anaesthetized with 1% pentobarbital (10 μl/g) and perfused with 0.9% saline and 4% cold paraformaldehyde successively. The brains were harvested and fixed with 4% paraformaldehyde at 4 °C overnight. The brain sections were prepared using a cryostat. Immunohistochemistry was processed as described next. Following incubation for 1 h in 10% bovine serum albumin with 0.3% Triton X-100 in 0.01 M PBS, the sections (30 μm) were incubated with anti-MMP-2 monoclonal antibody (1300) and anti-MMP-9 monoclonal antibody (1:500) overnight at 4 °C, and the sections were incubated with secondary antibody for 2 h. Immunostaining was visualized using 3,3′-diaminobenzidine. The sections were then counterstained with haematoxylin. Positive cells were visualized by adding DAB to the sections. Images of the immunostaining were digitally captured by using a Leica 2500 microscope.

#### ELISA {#FPar1}

The level of IL-17A in serum and hippocampal tissue extracts and IL-6 and IL-1β levels in hippocampal tissue extracts were measured with ELISA kits from R&D Systems. Data were collected and analysed using the Luminex-200 System version 2.3.

In vitro studies {#Sec13}
----------------

### Cell culture {#Sec14}

Immortalized BALB/C BECs \[bEnd.3; American Type Culture Collection (ATCC), Manassas, VA, USA\] derived from brain endothelial cells of a primary mouse were used as the BBB model. Cells were cultured in DMEM supplemented with 10 % foetal bovine serum and penicillin-streptomycin (0.6 × 105 μl^−1^). Cells were maintained at 37 °C and 5 % CO~2~ air atmosphere, and the medium was changed every 48 h.

### Recombinant IL-17A treatment {#Sec15}

The treatment was performed when cells were in a logarithmic phase of growth. bEnd.3 cells were seeded (1 × 10^6^ cells) in 5 cm × 5 cm flasks and incubated for 24 h at 37 °C and in 5% CO~2~ humidified atmosphere. The cells were treated with recombinant IL-17A (10, 50 and 100 ng/ml) for 24 h and collected.

### Immunofluorescence {#Sec16}

To evaluate the expression of IL-17A receptors in bEnd.3 cells, cells were fixed with 4% paraformaldehyde for 30 min. Unspecific binding was blocked by 5% BSA and 0.1% Triton X-100 solution at room temperature for 1 h. Cells were incubated with Rabbit anti-IL-17A receptor polyclonal antibody (1:50) in the blocking solution at 4 °C overnight. After three washes with PBS, the cells were incubated with corresponding FITC-conjugated goat anti-rabbit IgG (1:200) at 37 °C for 1 h, and the nuclei were stained with DAPI. Fluorescent images were acquired using a confocal microscope.

### Western blot {#Sec17}

Hippocampal tissues and bEnd.3 cells were homogenized in RIPA lysis buffer containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1.5 μg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride (PMSF). The samples were centrifuged at 12,000×*g* (4 °C) for 20 min, and the supernatants were harvested. Protein concentration was determined using a BCA kit. Proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF microporous membrane (Millipore, USA). The membranes were incubated with 5% non-fat milk at room temperature for 1 h and incubated overnight at 4 °C with primary antibodies: polyclonal rabbit anti-IL-17A receptor (1:500), monoclonal mouse anti-MMP-2 (1:1000), monoclonal mouse anti-MMP-9 (1:500), monoclonal mouse anti-claudin-5 (1:500) and monoclonal rabbit anti-occludin (1:1000). An antibody against GAPDH (1:1000) was also used as an internal standard. The membranes were incubated with goat anti-mouse secondary or goat anti-rabbit secondary antibodies at room temperature for 1 h and then detected with a chemiluminescent substrate. The relative densities of the protein bands were visualized and analysed by Image Lab software (Bio-Rad, Richmond, CA, USA) and NIH ImageJ software (Bethesda, MD, USA), respectively.

Statistical analysis {#Sec18}
--------------------

All values are presented as the mean ± SEM. The significance of the differences between groups was tested using a one-way ANOVA followed by post hoc least significant difference tests. *P* \< 0.05 was considered statistically significant.

Results {#Sec19}
=======

Tibial fracture surgery-induced cognitive impairment and treatment with anti-IL-17A Abs alleviated this effect {#Sec20}
--------------------------------------------------------------------------------------------------------------

To investigate the effect of surgery on cognitive function and whether IL-17A was involved, mice were injected i.p. with anti-IL-17A Abs or isotype-control Abs 30 min prior to tibial fracture surgery. Then, 24 h after surgery, we assessed learning and memory with behavioural tests. As shown in Fig. [2](#Fig2){ref-type="fig"}, compared with controls, the mice in the surgery group had a significant decrease in freezing time and increased number of learning trials (freezing: Sur group 15.67 ± 0.59 versus Con group 21.26 ± 0.73, *P* \< 0.001; number of learning trials: Sur group 64.83 ± 1.93 versus Con group 39.00 ± 1.39, *P* \< 0.01), which indicates a reduction in cognitive function. Treatment with anti-IL-17A Abs increased freezing time and decreased the number of learning trials compared to surgery (freezing: Sur+anti-IL-17A group 19.04 ± 0.61 versus Sur group 15.67 ± 0.59, *P* \< 0.001; number of learning trials: Sur+anti-IL-17A group 45.83 ± 1.82 versus Sur group 64.83 ± 1.93, *P* \< 0.01). Treatment with isotype-control Abs had no effect on learning and memory. Detailed training and learning data of contextual fear conditioning test was included in Additional file [1](#MOESM1){ref-type="media"}. These results suggested that tibial fracture surgery-induced cognitive impairment could be alleviated by treatment with anti-IL-17A Abs.Fig. 2Tibial fracture surgery-induced cognitive impairment and treatment with anti-IL-17A Abs alleviated this effect. The freezing time in the TFC test (**a**) and the number of learning trials in the Y maze test (**b**) were recorded to analyse the cognitive changes. \**P* \< 0.05 and \*\**P* \< 0.01 versus the Con group. ^\#\#^*P* \< 0.01 versus the Sur group. Data are presented as the mean ± SEM (*n* = 12)

Tibial fracture surgery increased serum and hippocampus IL-17A levels and hippocampus IL-17A receptors expression {#Sec21}
-----------------------------------------------------------------------------------------------------------------

The level of IL-17A in serum and the hippocampus 24 h after surgery was quantified by ELISA. As shown in Fig. [3](#Fig3){ref-type="fig"}a, b, tibial fracture surgery increased the level of IL-17A in serum and the hippocampus compared to controls, which was reversed by treatment with anti-IL-17A Abs. At the same time, we detected the expression of IL-17A receptors in the hippocampus by Western blot. The expression of IL-17A receptors in the hippocampus was also increased after surgery compared with controls, which was reversed by treatment with anti-IL-17A Abs (Fig. [3](#Fig3){ref-type="fig"}c, d). Treatment with the isotype control had no effect on the level of IL-17A or IL-17A receptors.Fig. 3Tibial fracture surgery increased serum and hippocampus IL-17A levels and hippocampus IL-17A receptor expression. The level of IL-17A in serum (**a**) and the hippocampus (**b**) 24 h after surgery was determined by ELISA. The expression of IL-17A receptors in the hippocampus 24 h after surgery was detected by Western blot (**c**). The expression of IL-17A receptors was quantified and normalized to GAPDH levels (**d**). \**P* \< 0.05 and \*\**P* \< 0.01 versus the Con group. ^\#\#^*P* \< 0.01 versus the Sur group. Data are presented as the mean ± SEM (*n* = 6)

Anti-IL-17A Abs attenuated the surgery-induced expression of IL-6 and IL-1β in the hippocampus {#Sec22}
----------------------------------------------------------------------------------------------

Since neuroinflammation plays a critical role in the pathophysiology of PND, to examine whether anti-IL-17A Abs could suppress surgery-induced neuroinflammation in aged mice, we tested the expression levels of IL-6 and IL-1β in the hippocampus 24 h after surgery by ELISA. As shown in Fig. [4](#Fig4){ref-type="fig"}, surgery significantly increased IL-6 and IL-1β content in the hippocampus compared to the control. However, injection with anti-IL-17A Abs 30 min prior to surgery attenuated the surgery-induced increased level of IL-6 and IL-1β. Injection with an isotype control had no effect on the expression of IL-6 and IL-1β. These results suggested injection with anti-IL-17A Abs could alleviate the production of pro-inflammatory factors.Fig. 4Anti-IL-17A Abs attenuated the surgery-induced expression of IL-6 and IL-1β in the hippocampus. The level of IL-6 (**a**) and IL-1β (**b**) in the hippocampus 24 h after surgery was determined by ELISA. \**P* \< 0.05 and \*\**P* \< 0.01 versus the Con group. ^\#\#^*P* \< 0.01 versus the Sur group. Data are presented as the mean ± SEM (*n* = 6)

Anti-IL-17A Abs reduced the surgery-induced EB leakage and expression of albumin in the hippocampus {#Sec23}
---------------------------------------------------------------------------------------------------

To further explore whether tibial fracture surgery could disrupt the integrity of the BBB and the modulatory effect of IL-17A, we detected leakage of EB in the hippocampus. Compared with the control group, the EB content in the hippocampus was notably increased 24 h after surgery. However, pretreatment with anti-IL-17A Abs reduced the surgery-induced EB leakage in the hippocampus (Fig. [5](#Fig5){ref-type="fig"}a). To further confirm the impact on the integrity of the BBB, we tested the albumin content in the hippocampus by Western blot. Pretreatment with anti-IL-17A Abs attenuated the surgery-induced increase in albumin content in the hippocampus (Fig. [5](#Fig5){ref-type="fig"}b). Pretreatment with the isotype control had no effect on the level of EB leakage and albumin. These results suggested that pretreatment with anti-IL-17A Abs reduced the surgery-induced BBB integrity disruption.Fig. 5Anti-IL-17A Abs reduced the surgery-induced EB leakage and expression of albumin in the hippocampus. The EB leakage (**a**) and the albumin content (**b**) tested by Western blot in the hippocampus 24 h after surgery were used to determine BBB integrity. \**P* \< 0.05 and \*\**P* \< 0.01 versus the Con group. ^\#\#^*P* \< 0.01 versus the Sur group. Data are presented as mean ± SEM (*n* = 4)

Anti-IL-17A Abs reversed the surgery-induced decrease of occludin and claudin-5 levels in the hippocampus {#Sec24}
---------------------------------------------------------------------------------------------------------

TJs, mainly occludin and claudin-5, are crucial factors responsible for BBB integrity. To further explore the impact on BBB integrity, we evaluated the level of occludin and claudin-5 by immunohistochemistry staining and Western blot. As shown in Fig. [6](#Fig6){ref-type="fig"}, surgery for tibial fracture induced a decrease in occludin and claudin-5 levels, which was reversed by pretreatment with anti-IL-17A Abs. Pretreatment with the isotype control had no effect on the levels of occludin and claudin-5 in that hippocampus. These results suggested that injection with anti-IL-17A Abs inhibited the surgery-induced reduction in occludin and claudin-5 levels.Fig. 6Anti-IL-17A Abs reversed the surgery-induced decrease of occludin and claudin-5 levels in the hippocampus. **a** The expression levels of occludin and claudin-5 in the hippocampus detected by immunostaining. Scale bar, 200 μm. **b** Quantification of occludin-positive and claudin-positive cells in the CA1 area of the hippocampus. **c** The expression levels of occludin and claudin-5 in the hippocampus detected by Western blot. **d** Quantification of occludin and claudin-5 levels. \**P* \< 0.05 and \*\**P* \< 0.01 versus the Con group. ^\#\#^*P* \< 0.01 versus the Sur group. Data are presented as the mean ± SEM (*n* = 4)

Anti-IL-17A Abs inhibited the expression of MMP-2 and MMP-9 induced by surgery {#Sec25}
------------------------------------------------------------------------------

MMPs, mainly MMP-2 and MMP-9, are vital components of the extracellular matrix proteasome, and contribute to BBB leakage by disrupting the neurovascular matrix and degrading occluding and claudin-5. Accordingly, we evaluated the levels of MMP-2 and MMP-9 in the hippocampus by immunohistochemistry staining and Western blot. As shown in Fig. [7](#Fig7){ref-type="fig"}, upon surgical treatment, MMP-2 and MMP-9 levels in the hippocampus of mice who underwent surgery were significantly higher than the levels in control mice, but these elevations were notably inhibited by anti-IL-17A Abs. Injection with the isotype control had no effect on the levels of MMP-2 or MMP-9 in the hippocampus. Full blots for Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"} were included in Additional file [2](#MOESM2){ref-type="media"}. These results suggested that injection with anti-IL-17A Abs reversed the surgery-induced increased levels of MMP-2 and MMP-9.Fig. 7Anti-IL-17A Abs inhibited the expression of MMP-2 and MMP-9 induced by surgery. **a** Immunostaining was used to detect the levels of MMP-2 and MMP-9 in the CA1 area of the hippocampus. Scale bar, 200 μm. **b** Quantification of MMP-2-positive and MMP-9-positive cells in the CA1 area of the hippocampus. **c** The expression levels of MMP-2 and MMP-9 in the hippocampus detected by Western blot. **d** Quantification of MMP-2 and MMP-9 levels. \**P* \< 0.05 and \*\**P* \< 0.01 versus the Con group. ^\#\#^*P* \< 0.01 versus the Sur group. Data are presented as the mean ± SEM (*n* = 4)

IL-17A upregulated the expression of IL-17A receptor in bEnd.3 cells {#Sec26}
--------------------------------------------------------------------

To ascertain whether IL-17A modulates the expression of IL-17A receptor proteins in bEnd.3 cells, immunofluorescence was used in the present study. As shown in Fig. [8](#Fig8){ref-type="fig"}, after incubation with different concentrations of IL-17A (10, 50 and 100 ng/ml) for 24 h, the expression of IL-17A receptors (in red) was greatly upregulated in bEnd.3 cells. These results suggest that IL-17A could upregulate the expression of IL-17A receptor in bEnd.3 cells.Fig. 8IL-17A upregulated the expression of IL-17A receptor in bEnd.3 cells. **a** Cells were stained with IL-17A receptor antibodies (red). IL-17A receptor expression in bEnd.3 cells was observed using confocal scanning. Blue staining represents DAPI. Scale bar, 200 μm. **b** Quantitative data of the mean intensity of IL-17A receptor fluorescence in bEnd.3 cells. All experiments were repeated three times. \**P* \< 0.05 and \*\**P* \< 0.01 versus the control group. Data are presented as the mean ± SEM

IL-17A decreased occludin and claudin-5 levels and increased MMP-2 and MMP-9 levels in bEnd.3 cells {#Sec27}
---------------------------------------------------------------------------------------------------

To further investigate how IL-17A disrupted BBB integrity, a cell culture model of bEnd.3 cells was used. bEnd.3 cells were cultured with different doses of IL-17A (10, 50 and 100 ng/ml) for 24 h. We examined the expression of TJs and MMPs by Western blot. As shown in Fig. [9](#Fig9){ref-type="fig"}, IL-17A treatment at concentrations of 50 ng/ml or greater for 24 h caused decreased expression of occludin and at concentrations of 10 ng/ml or greater caused claudin-5 decrease in bEnd.3 cells. Meanwhile, the MMP-2 and MMP-9 levels were increased at concentrations of 10 ng/ml or greater in bEnd.3 cells. These observations suggested that IL-17A might induce BBB disruption by decreasing occludin and claudin-5 protein expression levels and increasing levels of MMP-2 and MMP-9 proteins.Fig. 9IL-17A decreased occludin and claudin-5 levels and increased MMP-2 and MMP-9 levels in bEnd.3 cells. **a** The expression levels of occludin and claudin-5 in bEnd.3 cells 24 h after treatment with different doses of IL-17A detected by Western blot. **b** Quantification of occludin and claudin-5 in bEnd.3 cells. **c** The expression levels of MMP-2 and MMP-9 in bEnd.3 cells 24 h after treatment with different doses of IL-17A detected by Western blot. **d** Quantification of MMP-2 and MMP-9 levels in bEnd.3 cells. All experiments were repeated three times. \**P* \< 0.05 and \*\**P* \< 0.01 versus the control group. Data are presented as the mean ± SEM

Discussion {#Sec28}
==========

There is a close connection between IL-17A expression and the pathogenesis of CNS inflammatory diseases, including depression, ischaemic brain injury and multiple sclerosis \[[@CR31]--[@CR33]\]. However, it is not clear whether IL-17A is involved in the development of PND. In this study, we investigated the impact of IL-17A on cognitive change, neuroinflammation and BBB function after surgery. We found that surgery induced cognitive decline, elevation of IL-17A and IL-17A receptor levels, production of pro-inflammatory cytokines and BBB dysfunction. Treatment with anti-IL-17A Abs inhibited the surgery-induced neuroinflammation and cognitive decline via alleviating the BBB disruption.

Research has suggested that surgery could impair learning and memory abilities, especially in aged rodents. It manifests as deficits in exploratory behaviour and spatially based working memory \[[@CR34]\]. Contextual fear conditioning and Y maze tests are widely used to assess learning and memory abilities in rodents \[[@CR35], [@CR36]\]. Our results demonstrated that the freezing behaviour of mice decreased following surgery, whereas pretreatment with anti-IL-17A Abs could partially reverse the decrease in freezing time. In accordance with the contextual fear conditioning results, surgery increased the number of learning trials, which could be prevented by pretreatment with anti-IL-17A Abs. Taken together, our study indicated that pretreatment with anti-IL-17A Abs could inhibit cognitive deficits following surgery, indicating that IL-17A was involved in surgery-induced cognitive decline.Neuroinflammation plays an important role in many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and depression \[[@CR37]--[@CR39]\], and is believed to be a vital pathological mechanism of postoperative cognitive dysfunction \[[@CR40]\]. Levels of pro-inflammatory cytokines and markers have been shown to contribute to cognitive dysfunction and increase with age \[[@CR41]--[@CR43]\]. Surgery-caused increases of plasma cytokines are associated with the expression of cytokines in the hippocampus and memory impairment. Functional inhibition of IL-1β could mitigate the neuroinflammation, and peripheral TNF-α blockade could reduce the release of IL-1β and prevent neuroinflammation and postoperative cognitive decline \[[@CR44], [@CR45]\]. During CNS inflammation, IL-17A could also stimulate the production of pro-inflammatory cytokines and chemokines in CNS-resident cells and mediate leukocyte recruitment \[[@CR46], [@CR47]\]. Our results suggested that the level of IL-17A in serum and hippocampus, along with IL-6 and IL-1β in the hippocampus, increased 24 h after surgery compared with controls, and pretreatment with anti-IL-17A Abs abolished the increase in IL-6 and IL-1β following surgery. This in vivo experiment indicated that IL-17A played a role in surgery-induced neuroinflammation.

BBB disruption could precede neuroinflammation and cognitive dysfunction \[[@CR48], [@CR49]\]. And the immunity plays an important role in maintaining the function of the blood-brain barrier. Peripheral surgery may disrupt the BBB via complement activation and pro-inflammatory cytokines, such as TNF-α and high mobility group box-1 (HMGB1), which promotes brain inflammation \[[@CR50], [@CR51]\]. Furthermore, BBB disruption facilitates the migration of macrophages into the brain, and the hippocampal recruitment of macrophages is necessary for neuroinflammation and memory dysfunction, inducing cognitive decline following surgery \[[@CR52], [@CR53]\].

Some research has indicated that IL-17A decreased the integrity of the BBB, which contributes to the development of EAE \[[@CR31]\]. To unravel whether IL-17A contributed to neuroinflammation and cognitive dysfunction after surgery via impairing BBB integrity, we performed in vivo and in vitro experiments. Hania Kebir demonstrated that human CNS postmortem materials from heavily inflamed MS individuals showed more IL-17R expression on the endothelium compared with unaffected control individuals \[[@CR54]\]. We found that expression of IL-17A receptors was elevated following surgery, and IL-17A could increase the expression of IL-17A receptors in bEnd.3 cells. To evaluate the effect of surgery on BBB integrity and the role of IL-17A in the process, we tested EB extravasation and expression of albumin in the hippocampus and found obviously elevated EB extravasation and the expression of albumin 24 h after surgery, which was prevented by pretreatment with anti-IL-17A Abs. These data suggested that IL-17A is involved in surgery-induced disruption of BBB integrity.

Endothelial cells of the BBB are different from endothelial cells in other tissues because of continuous intercellular TJs, which are associated with BBB permeability and involved in many CNS diseases \[[@CR55], [@CR56]\]. The occludin and claudin families are important components of TJs \[[@CR57]\]. Our study demonstrated that surgery reduced the levels of occludin and claudin-5 in the hippocampus, which was inhibited by pretreatment with anti-IL-17A Abs. MMPs, a family of proteolytic enzymes, can break down the extracellular matrix proteins of the basement membranes and degrade the TJs \[[@CR58]\]. The involvement of MMP-2 and MMP-9 in BBB disruption has been reported in several ischaemic injury studies \[[@CR59], [@CR60]\]. In our study, expressions of MMP-2 and MMP-9 were significantly increased after surgery, which was obviously inhibited by pretreatment with anti-IL-17A Abs. Furthermore, our in vitro experiment suggested that IL-17A could decrease the expression of occludin and claudin-5 and increase the expression of MMP-2 and MMP-9 in bEnd.3 cells. These data further suggested that IL-17A is involved in surgery-induced disruption of BBB permeability.

Conclusions {#Sec29}
===========

In conclusion, our study revealed that IL-17A was involved in neuroinflammation and cognitive dysfunction after surgery in aged mice via BBB disruption. The in vitro study further confirmed that IL-17A could upregulate IL-17A receptor expression in bEnd.3 cells, increase MMP levels and decrease TJs, which disrupted BBB integrity. Our results might provide not only a better understanding of the role of IL-17A in PND but also a new therapeutic strategy for neuroinflammation-related diseases.

Additional files
================

 {#Sec30}

Additional file 1:Training and learning data. Table A. Freezing time before shock during the training period. Table B. Freezing time after shock 1 during the training period. Table C. Freezing time after shock 2 during the training period. Table D. Freezing time in contextual fear test. (*n* = 12). (PDF 73 kb) Additional file 2:Original full Western blotting images for Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}. The cross-section was not included in this study. (PDF 4281 kb)

Abs

:   Neutralizing antibody

AD

:   Alzheimer's disease

BBB

:   Blood-brain barrier

CNS

:   Central nervous system

DAPI

:   4,6-Diamidino-2phenylindole

DMEM

:   Dulbecco's modified Eagle's medium

EAE

:   Experimental autoimmune encephalomyelitis

EB

:   Evans blue

FBS

:   Foetal bovine serum

IL-17A

:   Interleukin-17A

MMP-2

:   Matrix metalloproteinase-2

MMP-9

:   Matrix metalloproteinase-9

MS

:   Multiple sclerosis

PD

:   Parkinson's disease

PMSF

:   Phenylmethylsulfonylfluoride

PND

:   Perioperative neurocognitive disorders

SDS-PAGE

:   Sodium dodecyl sulfate-polyacrylamide gel electrophoresis

TFC

:   Trace fear conditioning

TJs

:   Tight junctions
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